Prenetics Global (NASDAQ:PRE – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.32, FiscalAI reports. The company had revenue of $46.49 million for the quarter, compared to analyst estimates of $49.85 million. Prenetics Global had a negative net margin of 62.45% and a negative return on equity of 20.33%.
Prenetics Global Price Performance
Shares of NASDAQ:PRE opened at $19.37 on Tuesday. Prenetics Global has a 12 month low of $7.18 and a 12 month high of $23.63. The firm has a market capitalization of $326.77 million, a price-to-earnings ratio of -4.23 and a beta of 0.26. The business’s 50 day simple moving average is $19.17 and its 200-day simple moving average is $18.90.
Institutional Investors Weigh In On Prenetics Global
Large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new position in Prenetics Global in the fourth quarter worth about $1,302,000. Millennium Management LLC acquired a new stake in Prenetics Global in the fourth quarter valued at approximately $810,000. Marshall Wace LLP acquired a new stake in Prenetics Global in the 4th quarter worth approximately $788,000. Goldman Sachs Group Inc. acquired a new position in shares of Prenetics Global during the 4th quarter worth about $665,000. Finally, UBS Group AG raised its position in shares of Prenetics Global by 581.9% during the third quarter. UBS Group AG now owns 46,561 shares of the company’s stock valued at $619,000 after buying an additional 39,733 shares during the last quarter. 25.01% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Read Our Latest Research Report on PRE
Prenetics Global Company Profile
Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.
Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.
Read More
- Five stocks we like better than Prenetics Global
- 3 Infrastructure Stocks Built Around the Backbone of the Economy
- Moonshot to Money: Intuitive Machines Lands $600M Defense Win
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
